TRENTON, N.J. (AP) ‐ U.S. regulators on Friday approved expanded use of a fish oil-based drug for preventing serious heart complications in high-risk patients already taking cholesterol-lowering pills.
Vascepa was approved years ago for people with sky-high triglycerides, a type of fat in blood. The Food and Drug Administration allowed its use in a far bigger group of adults with high, but less extreme, triglyceride levels who have multiple risk factors such as heart disease and diabetes.
In patient testing, it reduced risks of potentially deadly complications including heart attacks and strokes about 25%.
Amarin, the drug’s maker, set a list price of $303.65 per month. What patients pay will vary by insurance, and Amarin said it will offer financial help.
The Irish drugmaker estimates the new approval makes Vascepa, which is pronounced vas-EE’-puh and also is called icosapent ethyl, appropriate for up to 15 million U.S. patients.
High triglycerides can clog arteries and boost chances of developing heart disease, suffering heart attacks or strokes, needing a bypass or artery-clearing procedure, or being hospitalized for chest pain ‐ just like high cholesterol and elevated blood pressure can do. 
|
